ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

faricimab

Also written as “Faricimab”, “Faricimab PFS Configuration” and “RO6867461”.

Its studies are mostly in Macular Edema · Macular Degeneration · Choroidal Neovascularization · Wet Macular Degeneration, led by Hoffmann-La Roche.

Drug pageFaricimab: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 25, 202217 company-led studies, 2 open or runningNext primary completion: Jan 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche172 open or runningphase 4since Jan 25, 2022Sep 3, 2013Jan 26, 2027phase 4 · NCT05224102

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2013First study: phase 1 study in Macular DegenerationFirst studyNCT01941082 · 24 enrolled · United States, United Kingdom
  2. Jun 12, 2015Phase 2 study in Choroidal NeovascularizationNCT02484690 · 273 enrolled · United States
  3. Mar 1, 2016Phase 2 study in Diabetic Macular EdemaNCT02699450 · 229 enrolled · United States
  4. Jan 31, 2017Phase 2 study in Choroidal NeovascularizationNCT03038880 · 76 enrolled · United States
  5. Dec 9, 2017Named faricimabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, RO6867461
  6. Aug 1, 20182 phase 3 studies in Diabetic Macular EdemaNCT03622593, NCT03622580
  7. Jan 29, 20192 phase 3 studies in Wet Macular DegenerationNCT03823300, NCT03823287
  8. Jun 12, 2020Phase 3 study in Diabetic Macular EdemaNCT04432831 · 1,479 enrolled · United States, Argentina, Australia and more
  9. Oct 19, 2020Phase 2 study in Diabetic Macular EdemaNCT04597918 · 99 enrolled · United States, Argentina, Canada and more
  10. Feb 3, 20213 phase 3 studiesNCT04740931, NCT04740905, NCT04777201
  11. Jan 25, 2022Phase 4 study in Diabetic Macular EdemaNCT05224102 · 218 enrolled · United States, India, Kenya and more
  12. Oct 4, 2022Phase 3 study in Neovascular Age-related Macular DegenerationNCT05569148 · 35 enrolled · United States
  13. Dec 11, 2023Phase 3 study in Choroidal Neovascularization Secondary to Pathologic MyopiaNCT06176352 · 280 enrolled · Australia, China, France and more
  14. Jan 24, 2025Phase 4 study in Neovascular Age-related Macular Degeneration (nAMD)NCT06795048 · 274 enrolled · United States, Australia, Canada and more

Ahead

  1. Jan 26, 2027Primary completion: phase 4 study in Diabetic Macular EdemaNCT05224102

TargetBeta

“A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema”NCIt, by rule
“Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06795048Neovascular Age-related Macular Degeneration (nAMD) · United States, Australia, Canada and more4Active, not recruitingOct 16, 2026274
NCT06176352Choroidal Neovascularization Secondary to Pathologic Myopia · Australia, China, France and more3CompletedMay 22, 2026280
NCT05569148Neovascular Age-related Macular Degeneration · United States3CompletedNov 10, 202235
NCT05224102Diabetic Macular Edema · United States, India, Kenya and more4Active, not recruitingJan 26, 2027218
NCT04777201Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more3CompletedSep 3, 20241,036
NCT04740931Macular Edema · United States, Argentina, Australia and more3CompletedAug 9, 2022729
NCT04740905Macular Edema · United States, Argentina, Australia and more3CompletedJul 6, 2022553
NCT04597918Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedDec 22, 202299
NCT04432831Diabetic Macular Edema · United States, Argentina, Australia and more3CompletedOct 11, 20231,479
NCT03823300Wet Macular Degeneration · United States, Argentina, Australia and more3CompletedOct 5, 2020658
NCT03823287Wet Macular Degeneration · United States, Canada, Germany and more3CompletedOct 26, 2020671
NCT03622593Diabetic Macular Edema · United States, Argentina, Australia and more3CompletedOct 19, 2020951
NCT03622580Diabetic Macular Edema · United States, Austria, Bulgaria and more3CompletedOct 20, 2020940
NCT03038880Choroidal Neovascularization · United States2CompletedJan 11, 201876
NCT02699450Diabetic Macular Edema · United States2CompletedSep 15, 2017229
NCT02484690Choroidal Neovascularization · United States2CompletedSep 26, 2017273
NCT01941082Macular Degeneration · United States, United Kingdom1CompletedFeb 201524

How it is read

Names in the registry

  • “Faricimab”, 15 entries
  • “Faricimab PFS Configuration”, 1 entry
  • “RO6867461”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.